Kairos Pharma, Ltd.
KAPA
$1.66
$0.000.00%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -23.22% | -64.85% | -109.26% | -84.68% | -134.85% |
| Total Depreciation and Amortization | -11.25% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -100.00% | 53.33% |
| Total Other Non-Cash Items | 21.65% | 716.84% | 733.96% | 29.92% | 93.76% |
| Change in Net Operating Assets | 82.84% | 38.47% | 59.38% | -1.45% | -402.94% |
| Cash from Operations | 25.68% | 20.02% | 13.00% | -99.42% | -21,468.00% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 1,184.79% | 2,436.62% | 2,436.62% | 2,436.62% | 157.84% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -93.25% | -92.02% | 884.10% | 761.90% | 901.78% |
| Cash from Financing | -57.37% | -53.85% | 29.72% | 25.25% | 3,640.25% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -113.54% | -98.35% | 173.03% | -24.37% | 1,527.96% |